BSc Biol, PhD Molecular Oncology
monica.martinez@iisgaliciasur.es
Tel: 986 217 463
Our research unit is formed by a multidisciplinary team composed of biologists, medical oncologists and pathologists with the common objective of understanding the molecular alterations involved in cancer to help in patients´ diagnosis and prognosis.
We have currently several projects on going aimed to find new biomarkers and molecular targets that can be used towards a precision medicine, opening new avenues in the therapeutic options, using tissue and liquid biopsies. We believe that our work is predestined to have a clear clinical application that could change cancer diagnosis and would help oncologists for personalized treatments.
• 2021 to present: Miguel Servet Researcher (ISCIII), Galicia Sur Health Research Institute (Hospital Álvaro Cunqueiro of Vigo, Spain)
• 2022 to present: Member of IISGS Equality Observatory, Galicia Sur Health Research Institute (Hospital Álvaro Cunqueiro of Vigo, Spain)
• 2018-2020: AECC investigator. Genomes and Disease lab, CIMUS (Santiago de Compostela, Spain)
• 2016: Jose Castillejo MECDE fellowship. Expression Regulation in Cancer lab. I3S & IPATIMUP, Porto (Portugal)
• 2014-2017: Postdoct. Molecular and Cellular Oncology lab. Biomedical Research Institute, Hospital Universitario 12 de Octubre (Madrid, Spain)
• 2014: EMBO Short-term Fellowship. Medical Genomics lab. Cancer Institute, UCL (London, UK)
• 2011-2014: Juan de la Cierva Postdoctoral MICINN Fellow. Molecular Oncology Unit, CIEMAT (Madrid, Spain)
• 2010: Postdoct. ECIMAT-CIBIO (Vigo, Spain – Porto, Portugal)
• 2005-2009: FPI PhD student (MINECO fellowship). Population Genetics and Cytogenetics Group (XB2). Universidade de Vigo (Vigo, Spain)
PREDOC STUDENTS
RESEARCH SUPPORT BIOINFORMATICIAN
MASTER’S STUDENT
• Manuel Pino González
LAB ASSISTANT
• Irene Alonso Álvarez, IISGS
EXTERNAL Cols
CHUS – Oncología Médica
• Dr. Luis León
• Dr Urbano Anido
CHUS – Anatomía Patológica
• Dr. Máximo Fraga
• Dr. Ihab Abdulkader
Hospital 12 de Octubre
• Dr. Jesús Paramio
• Dr. Cristian Suarez
CiMUS
• Dr. Jose Tubio
ONCOMET
• Dra. Laura Muinelo
• Dra. Clotilde Costa
INSTITUTO PORTUGUÊS DE ONCOLOGIA
• Dra. Carmen Jerónimo
• Suarez-Cabrera C, Estudillo L, Ramón-Gil E, Martínez-Fernández M, Peral J, Rubio C, Lodewijk I, Martín de Bernardo A, García-Escudero R, Villacampa F, Duarte J, de la Rosa F, Castellano D, Guerrero-Ramos F, Real FX, Malats N, Paramio JM, Dueñas M. BlaDimiR: A urine-based miRNA score for accurate bladder cancer diagnosis and follow-up. European Urology, in press (2022).
• Oitabén A, Fonseca P, Villanueva MJ, García-Benito C, López-López A, Garrido-Fernández A, González-Ojea C, Juaneda-Magdalena L, Lázaro ME, Martínez-Fernández M. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. Cancers (Basel), 14: 2626 (2022).
• Álvarez EG, Demeulemeester J*, Otero P*, Jolly C*, García-Souto D*, Pequeño-Valtierra A, Zamora J, Tojo M, Temes J, Baez-Ortega A, Rodriguez-Martin B, Oitaben A, Bruzos AL, Martínez-Fernández M, et al Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun,12: 6910 (2021).
• Segovia*, San José-Enériz* , Munera-Maravilla*, Martínez-Fernández M et al. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nature Medicine, 25: 1073–1081 (2019)
• Rubio C*; Martinez-Fernandez M*; et al. Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status. Clinical Cancer Research. 25, pp. 390 – 402 (2019)
• Dueñas, Perez-Figueroa…,Mónica Martínez-Fernández. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Scientific Reports, 9: 10362 (2019)
• Martínez Fernández M et al. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget. 6 – 39, pp. 42258 – 42333 (2015)
• Martínez Fernández M et al. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clinical Epigenetics. 7, pp. 109 (2015)
• Santos M*; Martínez Fernández M* et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Research. 74 – 22, pp. 6565 – 6642 (2014)
• Proyectos de excelencia, Axencia Galega de Innovación (Xunta de Galicia) “El potencial de la epigenética y el fenotipo inmune circulante en la respuesta a la inmunoterapia” (2022-2026)
• Proyecto de Investigación en Salud del ISCIII, AES2021, “UNA PERSPECTIVA EPIGENÉTICA EN LA ERA DE LA INMUNOONCOLOGIA”, (2022-2024)
• Proyecto Miguel Servet ISCIII: “Searching for potential predictive biomarkers for immunotherapy”, (2020-2024)
• Ideas Semilla AECC: “Estudio de nuevos mecanismos moleculares en la respuesta a inmmunoterapia”, (2020-2022)
• OCTOPUS project: Oncoloxía Customizada para Tratar Os PUlmónS (https://proxectooctopus.org/) funded by the Vigo Against Cancer Association, (2020-)
• Proyecto de Investigación en Salud del ISCIII, AES2019, “Ampliando el horizonte para los biomarcadores predictores de respuesta a inmmunoterapia”, (2020)
• AECC Investigator “Estudio del impacto funcional de la transducción de secuencias reguladoras mediada por retrotransposones altamente mutagénicos” (2018-2020).